However, NSCLC patients with BM now have a variety of treatment options available, including adjuvant chemotherapy, whole brain radiotherapy (WBRT) with or without stereotactic radiosurgery (SRS), immunotherapy, and epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) for those patients harboring activating EGFR mutations [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.